12400 HIGH BLUFF DRIVE, SAN DIEGO, CA
Investor Presentation
Evofem Biosciences Enters $706,304 Promissory Note with HUB Cyber Security
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
Fourth Amendment to Securities Purchase Agreement with Adjuvant
Termination of License and Supply Agreement with Windtree Therapeutics
Reports Fifth Consecutive Year of Net Sales Growth
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Notice of Exempt Offering of Securities
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Information Statement
Preliminary Information Statement
Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
PREM14A
Correspondence
Submission Upload